Evidence map›Paper›PMID 35963556›Full record

ArticleTravel medicine and infectious disease

Immunogenicity and safety of a RBD vaccine against SARS-CoV-2 in a murine model.

Andrés Díaz, Héctor Serrano-Coll, Yesica Botero, Alfonso Calderón, Ariel Arteta-Cueto, Bertha Gastelbondo, Camilo Guzmán, Ricardo Rivero, Caty Martínez, Tania Marquez and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Travel medicine and infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andrés DíazInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia.
Héctor Serrano-CollInstituto Colombiano de Medicina Tropical-Universidad CES, Medellín, Colombia.
Yesica BoteroInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia.
Alfonso CalderónInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia.
Ariel Arteta-CuetoDepartamento de Patología, Grupo de Investigaciones en Patología (GRIP-UdeA), Universidad de Antioquia, Medellín, Colombia.
Bertha GastelbondoInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia.
Camilo GuzmánInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia.
Ricardo RiveroInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia.
Caty MartínezInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia.
Tania MarquezFacultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Germán ArrietaInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia.
Salim MattarInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias, Departamento de Biología, Universidad de Córdoba, Colombia. Electronic address: smattar@correo.unicordoba.edu.co.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough more than half of the world's population is already vaccinated, the appearance of new variants of concern puts public health at risk due to the generation of new immunogens against the virus as a crucial and relevant strategy in the control of these new variants.

methodsA preclinical study used a potential vaccine candidate (RBD, SARS-CoV-2). Four groups of BALB/c mice were used, a control group, an adjuvant group, a group inoculated with one dose of RBD subunit protein, and the fourth group inoculated with two doses of RBD subunit protein.

resultsNo inflammatory or cellular changes were shown in the mice's anatomopathological evaluation. Higher kinetics and 75% seroconversion were obtained in the mice inoculated with two doses of RBD (P < 0.0001).

conclusionsThe application of two doses of the RBD vaccine candidate in BALB/c mice proved safe and immunogenic against SARS-CoV-2.

Indexed as

COVID-19Viral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesDisease Models, AnimalHumansMiceMice, Inbred BALB CSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral VaccinesCoronavirusPublic healthSpike glycoproteinSurveillanceVaccination

Identifiers

PMID35963556
PMCPMC9364943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.